Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.84 |
| ▸ | MET | P08581 | 1/20 | 0.84 |
| ▸ | NQO2 | P16083 | 1/20 | 0.84 |
| ▸ | FECH | P22830 | 1/20 | 0.84 |
| ▸ | CLK3 | P49761 | 1/20 | 0.84 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.81 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.81 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.81 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.81 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.81 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.81 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.81 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.81 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.81 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.81 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498448 | 1.00 | PLK1 (0.84) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498624 | 0.92 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL29397572 | 0.92 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498623 | 0.92 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498728 | 0.91 | PLK1 (0.98) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498730 | 0.91 | PLK1 (0.98) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL29360545 | 0.90 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498729 | 0.90 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL4726480 | 0.90 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL15835693 | 0.87 | PLK1 (0.77) | PLK1METNQO2FECHCLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664272-B2 | Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia | Temple University—Of the Commonwealth System of Higher Education (US) | 2014-03-04 | — | — | US | disclosed |
| US-8106033-B2 | (E)-2-(5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenylamino)acetic acid; antiproliferative; anticarcinogenic agent : solid tumors, leukemia; \"cytoproliferative\" diseases: atherosclerosis, fibrosis, Paget's disease; synergistic effect with other active ingredients | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100305059-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-12-02 | — | — | US | disclosed |
| US-20080161252-A1 | Composition and Methods For the Treatment of Proliferative Diseases | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008027049-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161252-A1 | Composition and Methods For the Treatment of Proliferative Diseases | CCNH, POLH, CCNO | PLK1 196/4885MET 254/4885NQO2 733/4885 |
| US-20100305059-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | DNMT3A, TET2, MCL1 | PLK1 1774/4885MET 185/4885NQO2 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.